Arcellx

Heading to the 2026 Tandem Meetings? Don’t miss our late-breaking poster abstract, presented by Principal Scientist Alexandra Witter, PhD. Stop by to learn about our innovative D-Domain binder, ask questions, and dive deeper into the data. Learn more: bit.ly/LateBreakingPr… #Tandem26 #MedEd

We are excited to connect with colleagues, collaborators, and leadership at the 2026 Tandem Meetings this February. Join us for one of our sessions where we will advance the conversation on our novel technology and present new health economics and outcomes research. Together, we’ll explore treatment sequencing and discuss why early CAR T access matters for patients living with #MultipleMyeloma. Learn more: bit.ly/Arcellx2026Tan… #Tandem26 #MedEd

Want to learn more about the data we presented at ASH? Tomorrow, our CEO @RamiElghandour is joining @endpts, along with EVP and Global Head of @KitePharma @cindy_perettie, for a fireside chat to discuss anito-cel as a potential treatment option for multiple myeloma patients. Register here: bit.ly/EndpointsatASH… #MedEd

Our Investor Relations event is live! A panel of clinician experts are discussing the latest data from the Phase 2 pivotal iMMagine-1 study in patients with relapsed or refractory multiple myeloma. Tune in: bit.ly/ArcellxEvent #Investors $ACLX

Today we announced new positive data from our Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory #multiplemyeloma. Read the full press release: bit.ly/ArcellxASH2025… Anito-cel is partnered with @KitePharma. #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd

Arcellx will present new iMMagine-1 data at #ASH25. We look forward to engaging with physicians and advocates, sharing insights that could help advance patient care in #multiplemyeloma. Read the release: bit.ly/ArcellxASH2025… #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd

Happy Thanksgiving! At Arcellx, we are grateful for the patients and physicians who participate in our clinical trials, our amazing team members, our partners at @KitePharma/@GileadSciences, and our shareholders. Wishing everyone a joyful holiday!

After leading teams at Fortune 100 companies, Chief People Officer Kate Aiken took a leap into the startup world, bringing her leadership philosophy with her. In this interview with @HRdotcom, Kate discusses how she builds trust and what shaped her as a leader in HR. Read more: bit.ly/KateAikenCPORe… #CSuite #ThoughtLeadership

We’re pleased to announce our presentations at #ASH25 – new data from our iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma and an analysis of geographic variation and systemic inequities of CAR-T therapy access in multiple myeloma in the U.S. Stop by our Medical Affairs booth to learn more about our novel binder, the D-Domain. We are excited to engage with the hematology community and share insights that could help advance patient care in multiple myeloma. #CellTherapy #MultipleMyeloma #RRMM #AnitoCel #CancerResearch #Innovation

On November 4, Chief Operating Officer Aileen Fernandes will join industry leaders during the “In pursuit of funding – how to create a strategy to advance early-stage drug development” panel discussion with @ftlive. This conversation will explore strategies on how #biotech companies can secure funding and stand out among competitors. To register: bit.ly/FTFinancingBio…. #MedEd

Well done, Heba Nowyhed, PhD, on being named the CSO award winner at this year’s @SFBusinessTimes C-Suite Leaders Awards. This award recognizes her leadership and passion for biotech innovation. #CSO #Leadership

Attending #IMS25? Visit our Medical Affairs team at booth #616 in Hall E to learn more about our lead clinical asset, anito-cel, in late-stage development for the treatment of patients with relapsed or refractory #multiplemyeloma, in collaboration with @KitePharma.

Congratulations to our Chief Scientific Officer, Heba Nowyhed, PhD, on being named a CSO finalist in the @SFBusinessTimes C-Suite Leaders Awards! This honor reflects her dedication to leadership, delivery of innovation in #CellTherapy, and impact on our company culture. Read more: bit.ly/3UB7yLv #CSO #Leadership

Attending #EHA2025? Learn the latest on our iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with #RRMM. We are excited to meet with #hematology physicians at the @EHA_Hematology Congress. #MedX #MedEd

We’re pleased to announce new positive data for our iMMagine-1 study of anito-cel in patients with RRMM will be shared at #EHA2025. We look forward to engaging with physicians at @EHA_Hematology Congress. Learn about our data: bit.ly/3FamFHs #MedEd #MedX

Happy #IWD2025! Hear CEO @Rami Elghandour on #BusinessofBiotech discuss why #inclusion is critical for a successful work environment and why women should always have a seat at the table: youtube.com/watch?v=y_ftzt…

Yesterday evening, we announced new positive data from our Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma, demonstrating anito-cel's potential to be a best-in-class treatment option. Anito-cel is partnered with @KitePharma . Read the full press release here: ir.arcellx.com/news/news-deta… Today, at 5:30 p.m. (PT) in Pacific Ballroom Salons 24-26, Ciara Freeman, M.D., Ph.D. will present these preliminary results during an oral presentation. #RRMM #AnitoCel #CellTherapy #CancerResearch

Attending #ASH24? Visit our Medical Affairs team at booth #1615 in Hall E to learn more about our lead clinical asset, anitocabtagene autoleucel (anito-cel), which is in late-stage development for the treatment of patients with relapsed or refractory multiple myeloma, in collaboration with @KitePharma We look forward to sharing our data and connecting with the broader #oncology physician community on the latest research innovations that aim to improve patients’ lives. #CellTherapy #AnitoCel #MultipleMyeloma #RRMM #CancerResearch

Our Chairman and CEO, @RamiElghandour, sat down with Business of Biotech podcast recently to discuss entrepreneurship and the importance of #DEI to creating exceptional teams that deliver outstanding performance, starting in the #CSuite. Listen here: bioprocessonline.com/solution/the-b…